Qinglin Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qinglin Tan has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Chen Chen
Department of Oncology, Dongguan Institute of Clinical Cancer Research, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital of Southern Medical University (Dongguan people’s hospital), Dongguan, China
1 shared publicationGuobiao Chen
Department of Thoracic Surgery, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People’s Hospital), Dongguan, China
1 shared publicationHanbin Zhang
Department of Clinical Pharmacy, Dongguan Institute of Clinical Cancer Research, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People’s hospital), Dongguan, China
1 shared publicationHuiting Mo
Department of Oncology, Dongguan Institute of Clinical Cancer Research, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital of Southern Medical University (Dongguan people’s hospital), Dongguan, China
1 shared publication- Jianming Lu
Department of Andrology, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, China
1 shared publication - Jiaqi Liao
Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 19
Unveiling HJURP as a Biomarker of Poor Prognosis and Immunotherapy Resistance in Lung Adenocarcinoma: A Multicenter Study
Background: Lung adenocarcinoma (LUAD) is the most common lung cancer, associated with high metastasis and low survival rates. Identifying reliable biomarkers is essential for better prognosis and treatment. Methods: In this study, we analyzed RNA sequencing data, mutation information, and clinical data from the TCGA-LUAD cohort and other multicenter datasets to investigate the role of Holliday junction recognition protein (HJURP) in LUAD. We employed immunohistochemistry in tissue microarray cohort to validate the prognostic significance of HJURP. The DepMap project was used to validate the effect of HJURP knockout in vitro. Results: Holliday junction recognition protein was identified as an adverse prognostic factor in the TCGA-LUAD cohort and diverse ethnic groups. Its expression correlated with poor immunotherapy outcomes, and HJURP knockout suppressed cancer cell proliferation. High HJURP expression was linked to increased mutation frequency, particularly in TP53 and TTN. Pan-cancer analysis also indicated HJURP as a poor prognostic factor in various solid tumors. Conclusions: Holliday junction recognition protein emerges as a significant biomarker in LUAD, consistently associated with poor prognosis across multiple cohorts. Its role in various oncogenic pathways and correlation with advanced disease stages underscore the potential of HJURP as a target for therapeutic intervention and as a marker for prognosis in LUAD.
- 1 January 2025
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 19
Open AccessUnveiling HJURP as a Biomarker of Poor Prognosis and Immunotherapy Resistance in Lung Adenocarcinoma: A Multicenter Study
Background: Lung adenocarcinoma (LUAD) is the most common lung cancer, associated with high metastasis and low survival rates. Identifying reliable biomarkers is essential for better prognosis and treatment. Methods: In this study, we analyzed RNA sequencing data, mutation information, and clinical data from the TCGA-LUAD cohort and other multicenter datasets to investigate the role of Holliday junction recognition protein (HJURP) in LUAD. We employed immunohistochemistry in tissue microarray cohort to validate the prognostic significance of HJURP. The DepMap project was used to validate the effect of HJURP knockout in vitro. Results: Holliday junction recognition protein was identified as an adverse prognostic factor in the TCGA-LUAD cohort and diverse ethnic groups. Its expression correlated with poor immunotherapy outcomes, and HJURP knockout suppressed cancer cell proliferation. High HJURP expression was linked to increased mutation frequency, particularly in TP53 and TTN. Pan-cancer analysis also indicated HJURP as a poor prognostic factor in various solid tumors. Conclusions: Holliday junction recognition protein emerges as a significant biomarker in LUAD, consistently associated with poor prognosis across multiple cohorts. Its role in various oncogenic pathways and correlation with advanced disease stages underscore the potential of HJURP as a target for therapeutic intervention and as a marker for prognosis in LUAD.
- Open Access
- 13 July 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (7) , 1-14
miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer
Trastuzumab resistance negatively influences the clinical efficacy of the therapy for human epidermal growth factor receptor 2 (HER2) positive gastric cancer (GC), and the underlying mechanisms remain elusive. Exploring the mechanisms and finding effective approaches to address trastuzumab resistance are of great necessity. Here, we confirmed that endoplasmic reticulum (ER) stress-induced trastuzumab resistance by up-regulating miR-301a-3p in HER2-positive GC cells. Moreover, we elucidated that miR-301a-3p mediated trastuzumab resistance by down-regulating the expression of leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) and subsequently activating the expression of insulin-like growth factor 1 receptor (IGF-1R) and fibroblast growth factor receptor 1 (FGFR1) under ER stress. We also found that intercellular transfer of miR-301a-3p by exosomes disseminated trastuzumab resistance. The present study demonstrated that exosomal miR-301a-3p could serve as a non-invasive biomarker for trastuzumab resistance, which was maybe a novel potential therapeutic target to overcome trastuzumab resistance and improve the curative effect of trastuzumab in HER2-positive GC patients.
- 13 July 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (7) , 1-14
Open AccessmiR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer
Trastuzumab resistance negatively influences the clinical efficacy of the therapy for human epidermal growth factor receptor 2 (HER2) positive gastric cancer (GC), and the underlying mechanisms remain elusive. Exploring the mechanisms and finding effective approaches to address trastuzumab resistance are of great necessity. Here, we confirmed that endoplasmic reticulum (ER) stress-induced trastuzumab resistance by up-regulating miR-301a-3p in HER2-positive GC cells. Moreover, we elucidated that miR-301a-3p mediated trastuzumab resistance by down-regulating the expression of leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) and subsequently activating the expression of insulin-like growth factor 1 receptor (IGF-1R) and fibroblast growth factor receptor 1 (FGFR1) under ER stress. We also found that intercellular transfer of miR-301a-3p by exosomes disseminated trastuzumab resistance. The present study demonstrated that exosomal miR-301a-3p could serve as a non-invasive biomarker for trastuzumab resistance, which was maybe a novel potential therapeutic target to overcome trastuzumab resistance and improve the curative effect of trastuzumab in HER2-positive GC patients.